Table 3.
Outcome | Topiramate group (n=38) | Naltrexone group (n=26) | Acamprosate group (n=28) |
---|---|---|---|
Abstinences | 29 (76.3%) | 15 (57.7%) | 17 (60.70%) |
Minor lapses | 02 (05.3%) | 03 (11.5%) | 02 (07.20%) |
Relapses | 07 (18.4%) | 08 (30.8%) | 09 (32.10%) |
Outcome | Topiramate group (n=38) | Naltrexone group (n=26) | Acamprosate group (n=28) |
---|---|---|---|
Abstinences | 29 (76.3%) | 15 (57.7%) | 17 (60.70%) |
Minor lapses | 02 (05.3%) | 03 (11.5%) | 02 (07.20%) |
Relapses | 07 (18.4%) | 08 (30.8%) | 09 (32.10%) |